Successful Efavirenz Dose Reduction in HIV Type 1-Infected Individuals with Cytochrome P450 2B6 *6 and *26
Hiroyuki Gatanaga(Saitama International Medical Center), Shinichi Oka(National Center for Global Health and Medicine), Tsunefusa Hayashida(Saitama International Medical Center), Noboru Takata(National Blood Transfusion Service), Sadao Kimura(Saitama International Medical Center), Hiroki Tsukada(Niigata University), K. Tsuchiya(National Center for Global Health and Medicine), Fumitake Gejyo(Niigata University of Pharmacy and Medical and Life Sciences), Katsuya Fujimoto(Hokkaido University), Takayoshi Koike(Hokkaido University), Ikuyo Sato(Sendai Medical Center), Masahiro Yamamoto(Kumamoto University), Shuzo Matsushita(Kumamoto University Hospital), Taishi Kuwahara, A. Kimura(Hiroshima University), T Shirasaka(Osaka National Hospital), Masahide Horiba(National Hospital Organization Saitama Hospital), Masanori Yoshino, Mikio Ueda(Ishikawa Prefectural Central Hospital), Motohiro Hamaguchi(Nagoya Medical Center)
Cited by 222
Related Papers
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)
|Journal of Thrombosis and Haemostasis|2006|7.1k
Nitrogen and phosphorus constrain the CO2 fertilization of global plant biomass
|Nature Climate Change|2019|528
Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis
|Annals of the Rheumatic Diseases|2007|413